Results 151 to 160 of about 417,892 (210)

Trends in <i>Arthrospira</i> sp. (Spirulina) Applications: A 15-Year Bibliometric Analysis and Systematic Review. [PDF]

Plants (Basel)
Hosseini H, Bounnit T, Saadaoui I.
europepmc   +1 more source

Strengthening health technology assessment in Greece: industry-identified barriers and recommendations. [PDF]

Front Public Health
George P, Eleftheria K, Kostas A.
europepmc   +1 more source

Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry [PDF]

Daron Acemoglu, Joshua Linn
core  

Some of the next articles are maybe not open access.

Related searches:

Pharmaceutical marketing

2022
Dr. Mohini Kalra, Dr.
Ranajit Nath, Ratul Bhowmik
openaire   +2 more sources

The Market for Pharmaceuticals

1998
Pharmaceuticals account for approximately 10 percent of total health care expenditures in OECD countries. The market for pharmaceuticals is best understood by examining the characteristics of supply and demand. The supply side may be described by the following features: The different pharmaceutical companies have a relatively small share in the overall
K, Bergenheim, U, Braun
openaire   +2 more sources

The Market for Pharmaceuticals

2009
One cannot possibly imagine present-day health care without pharmaceuticals. There are at least three reasons for this statement. (1) Pharmaceuticals represent a form of therapy that does not involve injuring or removing organs while permitting causal treatment (not only aimed at alleviating symptoms) in several instances. Chemotherapy, employed in the
Peter Zweifel, Friedrich Breyer, Mathias Kifmann   +2 more
openaire   +1 more source

A review of the genotoxicity of marketed pharmaceuticals

Mutation Research/Reviews in Mutation Research, 2001
Information in the 1999 Physician's Desk Reference as well as from the peer-reviewed published literature was used to evaluate the genotoxicity of marketed pharmaceuticals. This survey is a compendium of genotoxicity information and a means to gain perspective on the inherent genotoxicity of structurally diverse pharmaceuticals.
R D, Snyder, J W, Green
openaire   +2 more sources

A model for the Dutch pharmaceutical market

Health Economics, 1999
This paper develops a general-equilibrium model for the Dutch pharmaceutical market. The model derives the behaviour of patients, pharmacists, drug producers and parallel-importers from microeconomic principles and recognizes the interactions between the various actors. The latter is important since the general-equilibrium effects are sometimes at odds
E, Canton, E, Westerhout
openaire   +2 more sources